PubRank

Peter A Forsyth

Author PubWeight™ 41.57‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2009 1.80
2 Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009 1.53
3 Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 2007 1.50
4 Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res 2003 1.50
5 Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol Ther 2007 1.48
6 The p75 neurotrophin receptor is a central regulator of glioma invasion. PLoS Biol 2007 1.40
7 Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A 2010 1.39
8 Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst 2006 1.36
9 Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe 2013 1.33
10 Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 2008 1.24
11 Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci 2009 1.24
12 Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 2010 1.16
13 Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 2004 1.11
14 Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev 2010 1.09
15 Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006 1.08
16 Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res 2008 1.08
17 Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res 2010 1.08
18 Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res 2003 1.07
19 Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004 1.06
20 Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther 2010 1.05
21 Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. PLoS Biol 2008 1.03
22 REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest New Drugs 2012 1.02
23 Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors. Clin Cancer Res 2003 0.96
24 Melanoma in the brain: biology and therapeutic options. Melanoma Res 2012 0.95
25 Novel treatments for melanoma brain metastases. Cancer Control 2013 0.87
26 Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro Oncol 2013 0.87
27 Reproductive factors and risk of primary brain tumors in women. J Neurooncol 2014 0.86
28 Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo. PLoS One 2013 0.85
29 Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy. Trends Mol Med 2011 0.84
30 An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. Cancer Causes Control 2012 0.84
31 LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol 2014 0.83
32 Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon. PLoS One 2013 0.82
33 A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. Cancer 2011 0.81
34 Susceptibility of mantle cell lymphomas to reovirus oncolysis. Leuk Res 2009 0.79
35 Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience. J Neurooncol 2009 0.77
36 Toenail iron, genetic determinants of iron status, and the risk of glioma. Cancer Causes Control 2013 0.75
37 Leptomeningeal disease in oligodendroglial tumors: a population-based study. J Neurooncol 2011 0.75
38 A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature. Melanoma Res 2016 0.75